FindTrial
Sign In

Prospective observational study on the evaluation of Chinese patent drugs for cardiovascular end point events after coronary intervention in patients with coronary artery disease (PCI)

Prospective observational study on the evaluation of Chinese patent drugs for cardiovascular end point events after coronary intervention in patients with coronary artery disease (PCI)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOC-17012401
Enrollment
Unknown
Registered
2017-08-17
Start date
2017-09-30
Completion date
Unknown
Last updated
2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronory heart disease

Interventions

1:qishen capsule
2:herb medicine
3:only western medicine
4:chinse patent medicine

Sponsors

Fuwai Hospital Chinese Academy of medical scienses
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18 years and over; 2. The patient was diagnosed with coronary artery disease and underwent PCI treatment.

Exclusion criteria

Exclusion criteria: Subjects who are participating in other clinical trials or intervention studies

Design outcomes

Primary

MeasureTime frame
All causes of death: cardiovascular related death and other causes of death;—

Secondary

MeasureTime frame
Number of admissions for cardiovascular events; New complication / complication The incidence of angina pectoris and angina pectoris score; Seattle angina score;—

Contacts

Public ContactMa Lihong

Fuwai hospital Chinese Academy of medical scienses

mlh8168@163.com+86 18601902828

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026